KRAS and non-small cell lung carcinoma: Recent clinical trial reports highlighting the success of GI-4000 and TG01 as K-ras vaccines in NSCLC and PDAC respectively have also altered the conventional presumption dictating the inability of immune responses to target inner-membrane bound cancer antigens such as K-ras (Eriksen et al., 2017; Bournet et al., 2016; Chaft et al., 2014).